Thrivent Financial for Lutherans Trims Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Thrivent Financial for Lutherans lowered its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,887 shares of the company’s stock after selling 4,809 shares during the quarter. Thrivent Financial for Lutherans owned 0.05% of CRISPR Therapeutics worth $1,688,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of CRSP. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at $39,000. Western Pacific Wealth Management LP raised its holdings in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics in the third quarter valued at about $40,000. Spire Wealth Management boosted its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after acquiring an additional 1,482 shares during the period. Finally, MCF Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $80,000. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other CRISPR Therapeutics news, Director John Greene purchased 7,000 shares of the stock in a transaction on Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

CRSP has been the subject of several recent analyst reports. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Truist Financial lifted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a report on Wednesday, February 12th. Finally, Barclays lifted their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Stock Down 2.8 %

NASDAQ CRSP opened at $36.99 on Friday. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $68.39. The firm has a 50 day moving average of $43.10 and a two-hundred day moving average of $45.17. The stock has a market capitalization of $3.17 billion, a PE ratio of -8.46 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.